EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|September 14, 2005
Chronic Leg Ulcer in Patient With RA
Author(s)William J. Ennis, MD
This 64-year-old woman has had rheumatoid arthritis for 15 years; her hands show classic rheumatic changes. She also had a leg ulcer that had failed to heal in 8 years despite three skin grafts.
Advertisement
This 64-year-old woman has had rheumatoid arthritis for 15 years; her hands show classic rheumatic changes (A). She also had a leg ulcer that had failed to heal in 8 years despite three skin grafts (B). Such ulcers may be caused by vasculitis, venous or arterial disease, pyoderma gangrenosum, Felty's syndrome, trauma, or pressure.
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
Advertisement
Advertisement
Trending on Patient Care Online
1
9 Drugs Approved for Primary Care: Q3 2026
2
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
3
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
4
HIV Testing Before and During PrEP: Getting It Right
5